Hence, our objective was to assess the ability of PF to predict oncological outcomes in pancreatic carcinoma patients in comparison to other inflammation-related metrics (albumin, CRP, and CRP/Alb) as well as cellular indicators (the NLR, lymphocyte/monocyte ratio (LMR), and platelet/lymphocyte ratio (PLR). The gene discussed is ALB; the disease is exocrine pancreatic carcinoma.